Search Legislation

Commission Implementing Decision (EU) 2016/423Show full title

Commission Implementing Decision (EU) 2016/423 of 18 March 2016 authorising certain laboratories in Egypt, the United Arab Emirates and the United States to carry out serological tests to monitor the effectiveness of rabies vaccines in dogs, cats and ferrets (notified under document C(2016) 1609) (Text with EEA relevance)

 Help about what version

What Version

 Help about advanced features

Advanced Features

 Help about opening options

Opening Options

 Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

This item of legislation originated from the EU

Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).

Changes to legislation:

This version of this Decision was derived from EUR-Lex on IP completion day (31 December 2020 11:00 p.m.). It has not been amended by the UK since then. Find out more about legislation originating from the EU as published on legislation.gov.uk. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

Commission Implementing Decision (EU) 2016/423

of 18 March 2016

authorising certain laboratories in Egypt, the United Arab Emirates and the United States to carry out serological tests to monitor the effectiveness of rabies vaccines in dogs, cats and ferrets

(notified under document C(2016) 1609)

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Council Decision 2000/258/EC of 20 March 2000 designating a specific institute responsible for establishing the criteria necessary for standardising the serological tests to monitor the effectiveness of rabies vaccines(1), and in particular Article 3(2) thereof,

Whereas:

(1) Decision 2000/258/EC designates the Agence française de sécurité sanitaire des aliments (AFSSA) in Nancy, France, as the specific institute responsible for establishing the criteria necessary for standardising the serological tests to monitor the effectiveness of rabies vaccines. The AFSSA has now been integrated into the Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES) in France.

(2) Decision 2000/258/EC provides, inter alia, that the ANSES is to appraise laboratories in third countries that have applied for approval to carry out serological tests to monitor the effectiveness of rabies vaccines.

(3) The competent authority of Egypt has submitted an application for the approval of the Animal Health Research Institute in Giza, and the ANSES has established and submitted to the Commission a favourable appraisal report dated 29 September 2015 for this laboratory.

(4) The competent authority of the United Arab Emirates has submitted an application for the approval of the Central Veterinary Research Laboratory in Dubai, and the ANSES has established and submitted to the Commission a favourable appraisal report dated 29 September 2015 for this laboratory.

(5) The competent authority of the United States has submitted an application for the approval of the Atlanta Health Associates Rabies Laboratory in Cumming, the Virology Laboratory of Auburn University College of Veterinary Medicine in Auburn and the Rabies Laboratory of the Centers for Disease Control and Prevention in Atlanta (‘the US laboratories’), and the ANSES has established and submitted to the Commission a favourable appraisal report dated 29 September 2015 for the US laboratories.

(6) The Animal Health Research Institute in Giza, the Central Veterinary Research Laboratory in Dubai and the US laboratories should therefore be authorised to carry out serological tests to monitor the effectiveness of rabies vaccines in dogs, cats and ferrets.

(7) The measures provided for in this Decision are in accordance with the opinion of Standing Committee on Plants, Animals, Food and Feed,

HAS ADOPTED THIS DECISION:

Article 1U.K.

In accordance with Article 3(2) of Decision 2000/258/EC, the following laboratories are hereby authorised to perform serological tests to monitor the effectiveness of rabies vaccines in dogs, cats and ferrets:

(a)

Animal Health Research Institute

7 Nadi El-Said Street

P.O. Box 12618

Dokki

Giza

Egypt

(b)

Central Veterinary Research Laboratory

PO Box 597

Dubai

United Arab Emirates

(c)

Atlanta Health Associates Rabies Laboratory

309 Pirkle Ferry Road, Suite D300,

Cumming, GA 30040,

United States of America

(d)

Auburn University College of Veterinary Medicine

Department of Pathobiology, Virology Laboratory

261 Greene Hall

Auburn, AL 36849

United States of America

(e)

Centers for Disease Control and Prevention

Rabies Laboratory

1600 Clifton Road, NE

Atlanta, GA 30333

United States of America

Article 2U.K.

This Decision shall apply from 15 April 2016.

Article 3U.K.

This Decision is addressed to the Member States.

Done at Brussels, 18 March 2016.

For the Commission

Vytenis Andriukaitis

Member of the Commission

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the EU Official Journal
  • lists of changes made by and/or affecting this legislation item
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different versions taken from EUR-Lex before exit day and during the implementation period as well as any subsequent versions created after the implementation period as a result of changes made by UK legislation.

The dates for the EU versions are taken from the document dates on EUR-Lex and may not always coincide with when the changes came into force for the document.

For any versions created after the implementation period as a result of changes made by UK legislation the date will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. For further information see our guide to revised legislation on Understanding Legislation.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as adopted version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources